Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Tomer Mark, MD, David Jayabalan, Roger N. Pearse, MD/PhD, Jessica Stern, Jessica Furst, April Rambo, RN, John Harpel, MD/PhD, Tsiporah Shore, MD, Michael Schuster, MD, John P. Leonard, MD, Paul J. Christos, MPH, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2007) 110 (11): 3024.

https://doi.org/10.1182/blood.V110.11.3024.3024

Published: 2007

Journal Articles

Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.

Jeffrey Lee Wolf, MD, Paul Richardson, MD, Michael Schuster, MD, Annette LeBlanc, David Battleman, MD, MSc, Ian Walters, MD

Blood (2006) 108 (11): 3532.

https://doi.org/10.1182/blood.V108.11.3532.3532

Published: 2006

Journal Articles

Phase II Trial of Prochymal™ (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD).

Partow Kebriaei, MD, Luis Isola, MD, Erkut Bahceci, MD, H. Kent Holland, MD, Scott Rowley, MD, Joseph McGuirk, DO, Marcel Devetten, MD, Jan Jansen, MD, PhD, Roger Herzig, MD, Michael Schuster, MD, Joseph Uberti, MD, PhD

Blood (2006) 108 (11): 3231.

https://doi.org/10.1182/blood.V108.11.3231.3231

Published: 2006

Journal Articles

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

Brian A. Di Carlo, MD, Jessica L. Stern, Michael Schuster, MD, Tsiporah Shore, MD, John Harpel, MD, PhD, Roger Pearse, MD, PhD, Faiza Zafar, PA, Joanne Dymek, NP, Jessy Ryan, NP, David Jayabalan, MA, Selina Chen-Kiang, PhD, Scott Ely, MD, John P. Leonard, MD, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2006) 108 (11): 3538.

https://doi.org/10.1182/blood.V108.11.3538.3538

Published: 2006

Journal Articles

A Phase II Study of PXD101 in Advanced Multiple Myeloma.

Daniel Sullivan, MD, Seema Singhal, MD, Michael Schuster, MD, James Berenson, MD, Peter Gimsing, MD, Finn Wislöff, MD, Anders Waage, MD, Melissa Alsina, MD, Robert Gerwien, PhD, Anne Clarke, RN, MPH, Karen Moller, Chean Eng Ooi, PhD

Blood (2006) 108 (11): 3583.

https://doi.org/10.1182/blood.V108.11.3583.3583

Published: 2006

Journal Articles

FDG-PET May Be Helpful in the Determination of Transformation to an Aggressive Subtype in Low-Grade Lymphoma.

Lale Kostakoglu, MD, Stanley J. Goldsmith, MD, Amy Chadburn, MD, Erez Vidan, MD, Michael Schuster, MD, Paul Christos, M.S., MPH, Morton Coleman, MD

Blood (2005) 106 (11): 1927.

https://doi.org/10.1182/blood.V106.11.1927.1927

Published: 2005

NARROW

Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.

Phase II Trial of Prochymal™ (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD).

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

A Phase II Study of PXD101 in Advanced Multiple Myeloma.

FDG-PET May Be Helpful in the Determination of Transformation to an Aggressive Subtype in Low-Grade Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.

Phase II Trial of Prochymal™ (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD).

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

A Phase II Study of PXD101 in Advanced Multiple Myeloma.

FDG-PET May Be Helpful in the Determination of Transformation to an Aggressive Subtype in Low-Grade Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only